The research team, led by Jing Pan and Tzu-Shao Yeh of the Department of Nutrition and Food Hygiene at Nantong University in China, together with Luthfia Dewi of Universitas Muhammadiyah Semarang in Indonesia, focused their experiments on C2C12 cells, a widely used mouse skeletal muscle cell line that recapitulates key stages of muscle formation. These cells can be induced to behave like satellite cells, the resident stem cells of skeletal muscle, and to progress through the full differentiation program that turns undifferentiated myoblasts into mature, multinucleated myotubes, the cellular equivalent of muscle fibers. By treating these cells with boswellic acid and measuring changes at both the RNA and protein levels, the investigators were able to map the compound’s effects across the entire myogenic cascade.

The results were striking at multiple points along this cascade. Boswellic acid treatment produced a 17 percent increase in the number of Pax7-positive cells. Pax7 is the canonical marker of satellite cell identity and quiescent muscle stemness, and an expanded Pax7-positive population suggests that the compound preserves or expands the pool of cells capable of regenerating damaged or aging muscle tissue. This is a critical finding for the muscle aging field, because one hallmark of aged muscle is the depletion and dysfunction of its satellite cell reserve, leaving old muscles increasingly unable to repair themselves after injury, disuse, or disease.

Beyond stemness, the compound appeared to push cells more rapidly through the commitment and differentiation stages of muscle formation. The researchers quantified the relative messenger RNA levels of four master regulators of myogenesis: Pax7, Myf5, MyoD, and MyoG. These myogenic regulatory factors act in a choreographed sequence, with Pax7 maintaining the stem cell state, Myf5 and MyoD committing cells to the muscle lineage, and myogenin driving terminal differentiation and fusion into myotubes. Following boswellic acid treatment, the mRNA and protein levels of Myf5, MyoD, and MyoG were all significantly upregulated, indicating that the treated cells were accelerating through the myogenic differentiation program. The study also documented a two to four hour advancement in the myoblast renewal cycle, suggesting that the compound speeds the temporal rhythm by which muscle precursor cells proliferate and renew themselves before differentiating.

Protein-level confirmation came from Western blotting, a technique that separates proteins by molecular weight and detects them with specific antibodies. The team measured protein expression of Pax7, Myf5, MyoD, and MyoG, alongside loading controls such as beta-actin and GAPDH, and found the upregulation observed at the RNA level faithfully mirrored at the protein level. Immunofluorescence staining was used to visualize Pax7 and MyoD expression within individual cells, providing spatial confirmation that the molecular changes translated into shifts in the cellular populations themselves. Cell viability was assessed with the XTT assay, ensuring that the observed pro-myogenic effects were not simply an artifact of compound toxicity or stress-induced changes in cell behavior.

Perhaps the most translationally intriguing results concern hypertrophy, the enlargement of existing muscle fibers. Boswellic acid treatment significantly enhanced myotube hypertrophy through activation of the canonical hypertrophic signaling axis: the Akt-mTOR-p70S6K pathway. This pathway is the central growth-control circuit of skeletal muscle, integrating signals from insulin-like growth factor 1, mechanical loading, and nutrient availability to drive protein synthesis. Akt, or protein kinase B, phosphorylates and regulates downstream targets including mTOR, the mammalian target of rapamycin, which in turn activates p70S6K, a ribosomal protein S6 kinase that promotes ribosomal biogenesis and translation of muscle proteins. The researchers observed increased phosphorylation of all three nodes, indicating that boswellic acid switches on the same anabolic program engaged by resistance exercise and IGF-1 signaling.

The convergence of two effects, expanded stem cell activity and heightened anabolic signaling, is what distinguishes this study from many single-mechanism nutraceutical investigations. Aging muscle fails on both fronts: satellite cells become less numerous and less responsive, and the Akt-mTOR axis becomes progressively resistant to the anabolic stimuli of food intake and exercise, a phenomenon sometimes called anabolic resistance. A compound that simultaneously supports the regenerative stem cell compartment and re-energizes protein synthesis signaling could, in principle, address both dimensions of sarcopenia. The authors suggest that boswellic acid warrants consideration as a nutraceutical agent to enhance muscle differentiation and hypertrophy, and as a potential novel therapeutic strategy for mitigating muscle aging.

Boswellic acid itself has a long pharmacological history. It is the principal bioactive component of frankincense, the resin of Boswellia serrata and related species, and has been studied extensively for its anti-inflammatory properties, particularly its inhibition of 5-lipoxygenase and its effects on inflammatory pathways relevant to arthritis and inflammatory bowel disease. This new study extends its potential repertoire into muscle biology, a domain more commonly occupied by compounds such as creatine, leucine, and other branched-chain amino acids, and by pharmaceutical agents under development for sarcopenia. The triterpenoid structure of boswellic acid allows it to interact with multiple signaling proteins, which may explain its pleiotropic effects across the myogenic program and the growth-factor cascade.

The authors are careful to frame the work within its in vitro limits. All experiments were conducted in murine cell cultures, and the physiological concentration, absorption, and tissue distribution of boswellic acid in living organisms remain open questions. Satellite cell behavior in aged muscle is shaped by a complex niche of inflammatory signals, extracellular matrix changes, and vascular decline that a simplified cell culture cannot fully reproduce. The researchers explicitly state that additional in vivo and clinical investigations are warranted before any therapeutic relevance can be established. Human trials would need to establish safe dosing, bioavailability, and whether oral supplementation can achieve tissue concentrations capable of activating the pathways observed in culture.

Even so, the study adds to a growing scientific effort to identify accessible dietary compounds that can bias the balance between muscle loss and muscle regeneration in favor of renewal. With sarcopenia estimated to affect a substantial share of adults over sixty and to drive frailty, falls, and loss of independence, the search for safe, well-tolerated interventions is intensifying. If future animal and human studies confirm the mechanisms reported here, boswellic acid, a molecule that humans have consumed for millennia in the form of frankincense, could emerge as an unusually well-characterized candidate for supporting muscle health across the lifespan. For now, the finding stands as a compelling proof of concept: an ancient resin component, examined with modern molecular tools, appears capable of speaking the native language of regenerating muscle.

Subject of Research: Effects of boswellic acid on myogenic and hypertrophic signaling in skeletal muscle cells as a potential strategy against muscle aging

Article Title: Boswellic acid modulates myogenic and hypertrophic signaling in vitro: implications for muscle aging

Article References: Pan, J., Dewi, L., & Yeh, T.-S. (2026). Boswellic acid modulates myogenic and hypertrophic signaling in vitro: implications for muscle aging. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05596-9

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05596-9

Keywords: boswellic acid, satellite cells, sarcopenia, muscle aging, myogenesis, skeletal muscle hypertrophy, Akt-mTOR-p70S6K, myogenic regulatory factors, nutraceutical, C2C12 cells, muscle regeneration, frankincense